9月10日，Moderna盘中下跌3.38%，报135.585美元/股，成交额10.01亿美元，连续两个交易日走弱。
消息面上，此前Rothschild & Co Redburn将Moderna评级从中性下调至卖出，目标价设为81美元；瑞银虽维持150美元目标价，但给予中性评级，指出公司近期将迎来三项个体化新抗原疗法（INT）数据读出，包括今秋黑色素瘤三期数据及后续肾细胞癌、膀胱癌二期数据，市场对催化兑现存在不确定性。此外，生物科技板块整体表现疲弱，安进跌0.28%，吉利德科学跌0.74%，行业抛压延续。Moderna此前因mRNA癌症疫苗三期数据利好曾大幅飙升，近期股价持续回调，反映市场对短期涨幅消化及后续临床推进节奏的重新定价。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.